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Cytolytic T lymphocytes (CTL) can be raised against C57BL46 B-cell lymphomas from mice with LP-BM5
murine leukemia virus-induced AIDS (MAIDS). Adoptive transfer of polyclonal anti-MAIDS tumor CTL or two
CTL clones specific for the B6-1710 MAIDS lymphoma caused preservation of major histocompatibility
complex-restricted and allogeneic CTL responses, which may be interpreted as indices of protection from
LP-BM5 murine leukemia virus-induced immunodeficiency.
An immunodeficiency in which certain mouse strains are
inoculated with the LP-BM5 murine leukemia virus (MuLV)
isolate has been described (32). LP-BM5, a retrovirus complex
that originated from a preparation derived from C57BL mice
treated with whole-body irradiation (25), induced nontrans-
plantable reticulum cell neoplasms (18). Because, following
further passage, the viral isolate was observed to cause a
profound lymphoproliferative disorder and immunodeficiency,
it was renamed LP-BM5 (32). LP-BM5 is a mixture of MuLV
including ecotropic, recombinant mink cell cytopathic focus-
inducing (MCF) and replication-negative defective viruses.
The defective genome is the proximal agent causing the
immunodeficiency, however, with the ecotropic and perhaps
the MCF MuLV serving primarily as helper viruses (1, 5, 17,
19). Because LP-BM5-induced immunodeficiency bears a
number of characteristics similar to those of AIDS (4, 22, 23,
26, 30-33, 35, 38), including an increased incidence of terminal
B-cell lymphomas, it has been termed mouse AIDS (MAIDS).
Inbred mice vary widely in their susceptibilities to MAIDS with
C57BL/6 (B6) as the prototypic susceptible strain (29). Genes
governing resistance or susceptibility to MAIDS have been
mapped to the major histocompatibility complex (MHC) com-
plex (16, 29), most importantly to H-2D (29). Given the
well-known activity of cytolytic T lymphocytes (CTL) against
virus-infected cells, including in MHC class I-linked resistance
to MuLV-induced tumorigenesis (for example, see references
3, 6, 7, and 27), we have focussed on CTL responses in the
MAIDS system. In keeping with this notion, resistant A-strain
mice were rendered susceptible to LP-BM5-induced disease by
prior in vivo depletion of CD8+, but not CD4+, T cells (28).
To examine the involvement of specific CTL in MAIDS
pathogenesis, B6 mice were stimulated with the syngeneic
MAIDS-associated, CD5+ B-cell lymphomas, B6-1710 and
B6-1153, selected because of their homogeneity and expression
of the defective virus (22) and because in infected mice the
defective genome is expressed primarily by CD5+ B cells (20).
We reported previously (8) that B6 mice generate highly active
secondary CD8+ CTL responses specific for B6-1710 and
* Corresponding author. Mailing address: Department of Microbi-
ology, Dartmouth Medical School, 1 Medical Center Dr., Lebanon,
NH 03756. Phone: (603) 650-8607. Fax: (603) 650-6223.
B6-1153 but not other histocompatible tumors induced by
distinctive MuLV, including the AKR/Gross subset we have
studied extensively (for examples, see references 14, 15, and
36). Two types of CTL determinants were suggested (8), one
shared relatively equally by B6-1710 and B6-1153 and another
(immunodominant to the first) present at much higher func-
tional levels on B6-1710 than on B6-1153. The ability to
produce B6 anti-MAIDS tumor CTL by secondary stimulation
with spleen cells from mice infected with LP-BM5 or a
defective viral clone rescued by a molecularly cloned ecotropic
helper virus (12), but not ecotropic virus alone (8), suggested
(i) the importance of the defective genome in determining the
CTL epitopes and (ii) the possibility that anti-MAIDS tumor
CTL would be effective against LP-BM5-infected cells in B6
mice with developing MAIDS and thereby could influence the
progression of immunodeficiency.
In vivo adoptive transfer of polyclonal anti-MAIDS CTL or
tumor-primed effector cells. As a first approach towards testing
the potential relevance of anti-MAIDS CTL, polyclonal CTL
raised against the B6-1710 and/or B6-1153 tumors were tested
for their effect on LP-BM5-induced immunodeficiency in
approximately 7-week-old B6 mice. We chose a donor strain
histocompatible with and closely related to B6 (Fv-lb) but
carrying the n, rather than the b, allele of Fv-1, the B6.Fv-l1
congenic. Because both the ecotropic and MCF helper viruses
are B-tropic, the B-ecotropic MuLV-restrictive Fv-l product
should limit the infection of donor spleen cells by virus
originating from the tumor cells used to stimulate CTL pro-
duction. Indeed, in initial experiments mice receiving B6
anti-MAIDS tumor CTL and LP-BM5 were substantially more
able to mount immune responses than fully immunosup-
pressed mice receiving LP-BM5 MuLV alone, but the extent of
preservation of immune reactivity (compared with that of
unmanipulated mice) was somewhat limited, apparently due to
the transfer of infected donor cells containing LP-BM5, which
initiated disease in the B6 recipients. B6.Fv-l effector cells
highly lytic for the MAIDS tumors could be raised by second-
ary stimulation of tumor-primed splenic responder cells, in-
cluding cross-stimulation patterns of lysis of B6-1710 versus
B6-1153 target cells (data not shown) indistinguishable from
those published for B6 anti-MAIDS tumor CTL (8).
B6.Fv-l effectors were next employed in adoptive transfer
4679
TABLE 1. Effect of adoptive transfer of B6-1710 tumor-primed B6.Fv-ln spleen cells on LP-BM5 MuLV-induced
immunodeficiency in B6 mice
Target cell % specific lysisc
In vivo sequence and Stimulation E:T ratiob Anti-AKR/Gross MuLV Antiallogeneic
inoculation regimen' source Antiallogeneic_______
EdG2 AKR.H-2"SL P815 (H-2 )
Sequence A: day 20, 106 B.GV AKR.H-26SL1 100:1 87 84




Day 0, LP-BM5 AKR.H-2bSL1 100:1 12 14
AKR.H-2bSL1 20:1 6 6
Day 20, 106 B.GV P815 100:1 50
P815 20:1 34
Sequence C
Day 0, LP-BM5 AKR.H-2bSL1 100:1 36 41
AKR.H-2bSL1 20:1 19 22
Day 2, 3 x 107 1710-immunized P815 100:1 78
B6.Fv-1l spleen cellsd P815 20:1 65
Day 20, 106 B.GV
a Groups were composed of three C57BL/6 mice each. All injections were given intraperitoneally.
b E:T ratio, effector/target ratio.
c Percent specific lysis is defined as [(a - b)/c] x 100, where a is experimental counts per minute released, b is spontaneous counts per minute released, and c is freeze-thaw
releasable (about 80% of total) counts per minute. The values for percent specific lysis determined on the basis of individual 51Cr-release wells generally showed minimal
variation; the values of duplicate wells occasionally differed to a greater extent, but in all such cases the range of the values was +6% of the mean value.
d B6.Fv-1n mice were immunized with 106 B6-1710 tumor cells 10 days prior to removal of their spleens for transfer into B6 mice infected with 0.2 ml of the
MAIDS-inducing virus complex, LP-BM5.
experiments to determine their effect on the development of
MAIDS. The donor B6.Fv-ln cells were either fully differen-
tiated anti-MAIDS tumor CTL raised by homologous second-
ary stimulation or spleen cells from B6.Fv-l mice that were
primed with B6-1710 or B6-1153 tumor cells in vivo and
transferred without further culture or stimulation. Two "read-
out" responses were utilized to gauge the extent of immuno-
deficiency: the generation of primary allogeneic (anti-H-2")
CTL and the production of MHC-restricted CTL to AKR/
Gross MuLV-induced tumors following in vivo priming and in
vitro secondary stimulation with B.GV and AKR.H-2bSL1
tumor cells, respectively, as we have described elsewhere (14,
15). The H-2K"-restricted anti-AKR/Gross MuLV CTL, spe-
cific for an octameric peptide located in the viral transmem-
brane envelope protein p1SE, do not recognize MAIDS tu-
mors (8, 37). Adoptive transfer of both effector cells raised
against the immunodominant epitope of B6-1710 and those
raised against B6-1153, largely directed against the cross-
reactive determinant (8), resulted in a restoration of the
read-out responses suppressed in mice receiving only LP-BM5.
By using these criteria, substantial protection from MAIDS
was observed in five of seven experiments. Somewhat more
consistent protection was found with tumor-primed donor cells
as opposed to secondary restimulated CTL. The level of
restoration of the read-out CTL responses was often partial, as
depicted in Table 1; for example, both the MHC-restricted
anti-AKR/Gross MuLV CTL response to Ec G2 and AKR.H-
2bSL1 target cells after in vitro restimulation with AKR.H-
2bSLl, and especially the primary allogeneic response to P815,
were significantly restored by the transfer of the B6-1710
tumor-primed B6.Fv-1 cells (Table 1, compare regimens B
and C). Frequently, it was easier to alleviate inhibition of the
allogeneic response than that of the MHC-restricted, CTL
response, in keeping with the reported greater relative resis-
tance of allogeneic (versus MHC-restricted) CTL responses to
LP-BM5-induced immunodeficiency (13, 31).
Effect on LP-BM5-induced MAIDS by adoptive transfer of
CTL clones raised against MAIDS tumors. To confirm that the
adoptive transfer of CTL per se could interfere with the course
of LP-BM5-induced MAIDS, two interleukin-2 (Cetus Corpo-
ration, Emeryville, Calif.)-dependent clones, 0.3.1 and 10.2,
were obtained from bulk cultures of B6-1710-primed and
-restimulated CTL by limiting dilution. On the basis of their
lysis of B6-1710, but not B6-1153 or other target cells (Table
2), the 0.3.1 and 10.2 clones appear to be specific for the
immunodominant epitope preferentially expressed on B6-1710
(8). A third interleukin-2-dependent CTL clone, E4, originated
from a primary proliferative culture of naive B6 spleen cells
stimulated with irradiated B6-1710, that is, a superantigen
culture as described by Hugin et al. (21). E4, though possessing
less lytic activity than 0.3.1 or 10.2, also demonstrated a
preferential specificity for B6-1710. By indirect immunofluo-
rescence, all three CTL clones were only weakly positive at
best for NK1.1 (data not shown) but strongly expressed H-2Kb,
Thy 1.2, LFA-1, CD3, and cxI/, TcR (Table 3). Clone 0.3.1 was
CD8+, however, while both clones 10.2 and E4 were CD4
CD8-. The 0.3.1 and E4 clones expressed TcR V15 subunits,
whereas clone 10.2 was V,8 positive. Monoclonal antibody
blocking experiments showed that (i) clones 0.3.1 and 10.2
were K" restricted, (ii) LFA-1 was involved in recognition by all
three clones, and (iii) as predicted, only 0.3.1 showed a
functional dependence on CD8 (Table 4). All three CTL
clones were found to be MuLV negative on the basis of reverse
transcriptase assays (data not shown).
These CTL clones were employed in adoptive transfer
experiments in which between 1 x 106 and 2 x 106 donor CTL
cells were infused into B6 mice one or two times during the 2-
to 6-day period following injection of LP-BM5 MuLV. Subse-
quently the mice were immunized with B.GV tumor cells to
prime them for AKR/Gross virus CTL production, and later
the primed responder cells were cultured with appropriate
stimulator cells for primary allogeneic, or secondary anti-AKR/
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TABLE 2. Specificity of MAIDS CTL clones
Expt and CTL E:T Target cell % specific lysisc
clone" ratiob B6-1710 B6-1153 AKR.H-2bSL1
Expt 1
0.3.1 10:1 95 4 13
0.3.1 2:1 91 6 6
10.2 10:1 80 6 3
10.2 2:1 70 3 3
E4 10:1 28 12 3
E4 2:1 15 8 0
Expt 2
0.3.1 10:1 96 2 3
0.3.1 2:1 99 4 -1
E4 10:1 36 11 4
E4 2:1 27 9 1
a Polyclonal secondary anti-B6-1710 CTL that showed a high specific lytic
activity for only B6-1710 were cloned by limiting dilution with media containing
15 U of interleukin-2, 5 x 106 irradiated B6-1710 cells, and 106 irradiated B6
spleen cells (antigen and feeder cells) per ml. Alternatively, the E4 clone was
obtained from a primary in vitro culture of naive B6 spleen cells stimulated with
irradiated B6-1710 tumor cells at a responder to stimulator cell ratio of 2:1 (21).
CTL clones were maintained by feeding with interleukin-2 media thrice weekly
and restimulation with antigen and feeder cells every other week.
b E:T ratio, effector/target ratio.
Other 51Cr-release experiments have shown additional targets, including
clone 18-5 (10, 11), EcG2, P815, LB27.4 (a murine H-2"' B-cell hybrid), and
YAC-1 (a natural killer cell target) to be insusceptible to lysis by these CTL
clones. The level of spontaneous release of targets in both experiments was 20% or
lower. Percent specific lysis was determined as described in Table 1, footnote c.
Gross MuLV, CTL generation to measure the degree of
immunodeficiency. Transfer of the 0.3.1 CTL clone was effec-
tive in substantially restoring the read-out antiviral CTL re-
sponse and completely restored allogeneic CTL production,
relative to responses by mice receiving only LP-BM5 (Table 5,
TABLE 4. CTL recognition by MAIDS CTL clones'
Inhibition of lysis by
Restriction pretreatment withClone element antibody against:
CD4 CD8 LFA-1
0.3.1 K: _ + +
10.2 K" _ - +
E4 ND"b _ +
a As determined by 51Cr-release antibody blocking assays in which for
restriction element determination the lysis of antibody treated targets was
compared with that of targets pretreated with media alone to arrive at a
percentage of lysis blocked. Alternatively CTL clones were pretreated by
antibodies to CD4, CD8, or LFA-1 and tested against untreated 51Cr-labeled
targets. The level of blocking was defined as -29% inhibition (-) or .80%
inhibition (+).
bND, not determinable.
experiment 1). In repeat experiments, adoptive transfer of
clone 0.3.1 was also able to protect from immunodeficiency, as
evidenced by restoration of either the allogeneic and/or the
MHC-restricted antiviral CTL responses in five of seven
experiments. Although the protection from LP-BM5-induced
immunodeficiency was frequently partial, especially for the
antiviral CTL response, in one experiment the anti-AKR/
Gross MuLV (as well as the anti-allogeneic) C1'L response was
fully restored. The E4 CTL clone was also shown to restore the
read-out CTL responses in two of three experiments, including
one in which both the anti-AKR/Gross MuLV and anti-H-2d
allogeneic CIL responses were essentially completely restored
(Table 5, experiment 2). In the same experiment, a parallel
transfer of slightly larger numbers of a control CTL clone (G8;
see the description below) provided no protection from LP-
BM5 immunodeficiency. Thus, despite its derivation from a
superantigen-stimulated proliferation assay and CD4- CD8-
TABLE 3. Characteristics of MAIDS CTL clones
Results for clone
Cell surface 0.3.1 (expt 1) 10.2 (expt 1) E4 (expt 2)antigen" ______________ ______________ ______________
% of cells + ATMFIb % of cells + ATMFI % of cells + ATMFI
DNP (control) 5 5 4
Thyl.2 99 1,292 100 1,327 100 1,372
CD8 100 405 5 0 8 8
K6 100 530 100 396 99 781
Mac-1 (control) 5 5 5
LFA-1 100 1,372 100 1,415 99 2,282
CD4 2 -1 4 0 3 -9
V131 1 -1 6 0 4 2
V,6 2 0 4 0 3 2
P3 (control) 4 6 4
VP5.1+5.2 100 124 5 0 98 307
V113 6 1 7 1 4 -1
HuT cells (control) 4 5 3
V138 4 0 99 164 3 2
TNP (control) 4 5 15c
CD3 99 144 98 114 100 455
a/, TcR 100 74 97 61 94 89
y/ TcR 16 4 6 1 21 3
a As determined by flow cytometric analysis on a Becton Dickinson FACScan.
b ATMFI, A total mean fluorescence intensity, was calculated by subtracting the indicated isotype control TMFI from each appropriate experimental TMFI.
cNegative control cells were stained with media followed by secondary fluorescein isothiocyanate-conjugated antibody.
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TABLE 5. Effect of adoptive transfer of CTL clone 0.3.1 or E4 on the LP-BM5 MuLV-induced immunodeficiency of B6 mice
Target cell % specific lysisc
Expt and in vivo sequence and Stimulation E:T ratiob Anti-AKR/Gross MuLV Antiallogeneic
inoculation regimen' source Antiallogeneic________P1_
EcTG2 AKR.H-2hSL1 P815 (H-2d)
Expt 1
Sequence A: day 10, 106 B.GV
Sequence B: day 0, LP-BM5 virus; day 10,
106 B.GV
Sequence C: day 0, LP-BM5 virus; days 3 and
6, 2 x 106 clone 0.3.1; day 10, 106 B.GV
Expt 2
Sequence A: day 14, 106 B.GV
Sequence B: day 0, LP-BM5 virus; day 14,
106 B.GV
Sequence C: day 0, LP-BM5 virus; day 3,
1.2 x 106 clone E4 (IV); day 14, 106 B.GV
Sequence D: day 0, LP-BM5 virus; day 3,


































































































































a Groups were composed of three B6 mice each. All injections were given intraperitoneally unless otherwise noted. Mice in experiment 1 received 0.15 ml and in
experiment 2, 0.25 ml of the LP-BM5 virus.
b E:T ratio, effector/target ratio.
c Percent specific lysis was determined as described in Table 1, footnote c.
phenotype, E4 was similar to clone 0.3.1 in terms of its ability
to interfere with LP-BM5-induced MAIDS.
In contrast, no consistent evidence for interference with
LP-BM5-induced immunodeficiency was observed for the 10.2
CTL clone (three of three experiments), including in an
experiment in which 0.3.1 demonstrated substantial restoration
of read-out responses. With regard to its inability to interfere
with LP-BM5-induced immunodeficiency, clone 10.2 was thus
similar to several control CTL clones tested, including CTLL-2
(9), the interleukin-2 indicator line which in our hands is
nonlytic, and G8. The anti-AKR/Gross MuLV G8 clone is
highly active, K" restricted (2, 10), and specific for an octameric
peptide of pl5E not encoded by the defective virus and altered
so as not to be recognized in the B-ecotropic helper virus of
MuLV (24), and it recognizes the MAIDS tumors very poorly,
if at all. G8 failed to interfere with LP-BM5-induced immuno-
deficiency in three of three experiments, including head-to-
head comparisons with protective clones (e.g., see Table 5,
experiment 2).
Collectively, these results thus demonstrate that polyclonal
anti-MAIDS tumor CTL and some CTL clones directed
against the B6-1710 B-cell lymphoma can interfere with LP-
BM5 MuLV pathogenesis in MAIDS-sensitive B6 mice. The
basis for the inability of the 10.2 CTL clone to show such
protection is unclear: the protective E4 CTL clone is always
less lytically active than clone 10.2 in 51Cr-release assays (e.g.,
see Table 2). Clone 10.2 appears to have a target cell specificity
and class I K* restriction element requirement indistinguish-
able from that of the protective clone 0.3.1. The three CTL
clones produce gamma interferon at roughly equivalent levels
J. VIROL.4682 NOTES
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(data not shown). The CD4- CD8- cell surface phenotype of
clone 10.2 appears unrelated to its inability to protect, because
clone E4 is also CD4- CD8-. Although it is possible that an
adhesion molecule or some other cell surface molecule may be
missing, the other phenotypic characteristics of clone 10.2 are
indistinguishable from those of the two protective CTL clones,
except for the a-chain subunit of the o/I8 TcR. Clones 0.3.1 and
E4 are VP5+, whereas clone 10.2, like most CD4- CD8- T
cells immortalized by radiation leukemia virus (34), isVP8+.
The common usage of V,B5 by the two protective CTFL clones
is also intriguing in that V,5 (along with VPi11) TcR-bearing T
cells have been reported to expand in response to a viral
superantigen on the B6-1710 tumor (21). Whether interference
with LP-BM5-induced MAIDS correlates with the utilization
of V,5 type TcR and/or recognition of superantigen determi-
nants remains to be determined in further experiments. Re-
gardless of the precise mechanism by which protective clones
recognize MAIDS tumors in vitro and nontransformed cells in
LP-BM5-infected mice in vivo to restore immune reactivity,
these experiments clearly show the potential relevance of CTL
in the disease process and offer promise that immunization
strategies to raise such CTL in MAIDS-susceptible mice may
also provide protection from LP-BM5-induced immunodefi-
ciency.
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